<SEC-DOCUMENT>0001193125-13-090814.txt : 20130305
<SEC-HEADER>0001193125-13-090814.hdr.sgml : 20130305
<ACCEPTANCE-DATETIME>20130305090602
ACCESSION NUMBER:		0001193125-13-090814
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20130304
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130305
DATE AS OF CHANGE:		20130305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		13663973

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d498361d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of Earliest Event Reported): March 5, 2013 (March&nbsp;4, 2013) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 430, Broomfield, CO 80021 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s Telephone Number, Including Area Code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5 &#151; Corporate Governance and Management </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;4, 2013, ARCA biopharma, Inc. (the &#147;Company&#148;) filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company, as amended (the
&#147;Amendment&#148;), to implement a six-for-one reverse split of its common stock (the &#147;Reverse Split&#148;), as previously authorized and approved at the Company&#146;s special meeting of stockholders on February&nbsp;25, 2013. The Reverse
Split was effective as of 5:01&nbsp;p.m. (Eastern Time) on March&nbsp;4, 2013, and the Company&#146;s common stock will continue trading on The NASDAQ Capital Market on a post-split basis on March&nbsp;5, 2013. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result of the Reverse Split, every six shares of issued and outstanding common stock were combined into one share of issued and outstanding common
stock. In addition, the Reverse Split effected a proportionate adjustment to the per share exercise price and the number of shares issuable upon the exercise or settlement of all outstanding options and warrants to purchase shares of the
Company&#146;s common stock, and the number of shares reserved for issuance pursuant to the Company&#146;s existing stock option plans were reduced proportionately. No fractional shares will be issued as a result of the Reverse Split, and
stockholders who otherwise would be entitled to a fractional share will receive, in lieu thereof, a cash payment based on the closing sale price of the Company&#146;s common stock as reported on The NASDAQ Capital Market on March&nbsp;4, 2013.
Because the Amendment did not reduce the number of authorized shares of the Company&#146;s common stock, the effect of the Amendment is to increase the number of shares of common stock available for issuance relative to the number of shares issued
and outstanding.&nbsp;The Reverse Split did not alter the par value of the Company&#146;s common stock or modify any voting rights or other terms of the common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A copy of the Amendment, as filed with the Secretary of State of the State of Delaware on March&nbsp;4, 2013, is attached hereto as Exhibit&nbsp;5.1. On March&nbsp;5, 2013, the Company issued a press
release announcing the Reverse Split. A copy of the press release is attached hereto as Exhibit&nbsp;99.1. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;9 &#151; Financial
Statements and Exhibits </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;5.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Amendment to Restated Certificate of Incorporation.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA Announces Reverse Stock Split&#148; dated March 5, 2013.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: March&nbsp;5, 2013 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>/s/ Christopher D. Ozeroff </U></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Christopher D. Ozeroff</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: Senior Vice President</FONT></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d498361dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 5.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATE OF AMENDMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OF </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>OF </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA B<SMALL>IOPHARMA</SMALL>, I<SMALL>NC</SMALL>.</B>, a corporation organized and existing under and by virtue of the General
Corporation Law of the State of Delaware (the &#147;<B><I>DGCL</I></B>&#148;), does hereby certify: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>F<SMALL>IRST</SMALL>:
</B>The name of the corporation is ARCA Biopharma, Inc. (the &#147;<B><I>Corporation</I></B>&#148;). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>ECOND</SMALL>: </B>The date of filing of its original Certificate of Incorporation with the Secretary of State of the State of
Delaware was March&nbsp;16, 2004 under the name &#147;Nuvelo Merger Sub, Inc.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HIRD</SMALL>: </B>The Board of
Directors (the &#147;<B><I>Board</I></B>&#148;) of the Corporation, acting in accordance with the provisions of Sections&nbsp;141 and 242 of the DGCL, adopted resolutions amending its Amended and Restated Certificate of Incorporation, as amended, as
follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. </B>Article&nbsp;IV, Section A of the Restated Certificate of Incorporation of the Corporation is hereby
amended to add the following provisions in their entirety to the existing provisions of Article IV: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Effective at 5:01 p.m. Eastern time, on the date of the filing of this Certificate of Amendment to the Amended and
Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the &#147;Effective Time&#148;), the shares of the Corporation&#146;s Common Stock, par value $0.001 per share, issued and outstanding immediately prior to
the Effective Time and the shares of Common Stock issued and held in the treasury of the Corporation immediately prior to the Effective Time shall be combined into a smaller number of shares such that each six (6)&nbsp;shares of issued and
outstanding Common Stock immediately prior to the Effective Time are combined into one validly issued, fully paid and nonassessable share of Common Stock, par value $0.001 per share. Notwithstanding the immediately preceding sentence, no fractional
shares shall be issued and, in lieu thereof, upon surrender after the Effective Time of a certificate which formerly represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time, any person who would
otherwise be entitled to a fractional share of Common Stock as a result of the combination, following the Effective Time (after taking into account all fractional shares of Common Stock otherwise issuable to such holder), shall be entitled to
receive a cash payment equal to the fraction to which such holder would otherwise be entitled multiplied by the fair value of the Common Stock on the date of the Effective Time, as determined by the Board of Directors. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each stock certificate that, immediately prior to the Effective Time,
represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number
of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been combined (as well as the right to receive cash in lieu of fractional shares of Common Stock after
the Effective Time), provided however, that each person of record holding a certificate that represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall receive, upon surrender of such
certificate, a new certificate evidencing and representing the number of whole shares of Common stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been combined.&#148;;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>F<SMALL>OURTH</SMALL></B><SMALL></SMALL>: Thereafter, pursuant to a resolution by the Board of Directors, this Certificate
of Amendment was submitted to the stockholders of the Corporation for their approval in accordance with the provisions of Section&nbsp;211 and 242 of the DGCL. Accordingly, said proposed amendment has been adopted in accordance with Section&nbsp;242
of the DGCL. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, ARCA
B<SMALL>IOPHARMA</SMALL>, I<SMALL>NC</SMALL>.</B> has caused this Certificate of Amendment to be signed by its duly authorized officer this 4</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> day of March, 2013. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA B<SMALL>IOPHARMA</SMALL>, I<SMALL>NC</SMALL>.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Christopher D. Ozeroff</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>HRISTOPHER</SMALL> D. O<SMALL>ZEROFF</SMALL></B></FONT></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d498361dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g498361arca.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Christopher D. Ozeroff </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and General Counsel </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2100 </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA BIOPHARMA,
INC. ANNOUNCES REVERSE STOCK SPLIT </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, March&nbsp;5, 2013</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a
biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation, heart failure and other cardiovascular diseases, today announced a 6-for-1 reverse split of its common stock. The reverse stock split became effective on
March&nbsp;4, 2013 at 5:01 p.m. Eastern Time, and ARCA&#146;s common stock will continue trading on The NASDAQ Capital Market, on a split-adjusted basis, when the market opens on Tuesday, March&nbsp;5, 2013. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the effective time of the reverse stock split, every six shares of ARCA&#146;s issued and outstanding common stock converted automatically into one
issued and outstanding share of common stock, without any change in the par value per share. The reverse stock split reduced the number of shares of ARCA&#146;s issued and outstanding common stock from approximately 19.1&nbsp;million shares to
approximately 3.2&nbsp;million shares. In addition, the reverse stock split effected a proportionate adjustment to the per share exercise price and the number of shares issuable upon the exercise or settlement of all outstanding options and warrants
to purchase shares of ARCA&#146;s common stock, and the number of shares reserved for issuance pursuant to ARCA&#146;s existing stock option plans were reduced proportionately. No fractional shares will be issued as a result of the reverse stock
split, and stockholders who otherwise would be entitled to a fractional share will receive, in lieu thereof, a cash payment based on the closing sale price of ARCA&#146;s common stock as reported today on the NASDAQ Capital Market. ARCA&#146;s
transfer agent will provide instructions to stockholders regarding the process for exchanging shares. Additional information regarding the reverse stock split can be found in ARCA&#146;s definitive proxy statement filed with the Securities and
Exchange Commission on February&nbsp;1, 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The purpose of the reverse stock split is to raise the per share trading price of ARCA&#146;s
common stock to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on The NASDAQ Capital Market. As previously disclosed, in order to maintain ARCA&#146;s listing on The NASDAQ Capital Market, the common
stock must have a minimum closing bid price of $1.00 per share for a minimum of ten consecutive trading days prior to April&nbsp;9, 2013. There can be no assurance that ARCA will regain compliance with the minimum bid price requirement. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product
candidate, Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an
investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with the Laboratory
Corporation of America (LabCorp), under which LabCorp has developed a companion genetic test for Gencaro. For more information please visit <U>www.arcabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release and the associated presentation may contain
&#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding genetic variations to predict individual
patient response to Gencaro, Gencaro&#146;s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention
treatment, and ARCA&#146;s ability to regain compliance with NASDAQ Capital Market minimum bid price. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could
differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be
sufficient to meet the Company&#146;s business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s intellectual
property; risks related to the drug discovery and the regulatory approval process; the impact of competitive products and technological changes; and the impact of the reverse split on ARCA&#146;s continuing share price. These and other factors are
identified and described in more detail in ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2011 and subsequent filings. The Company disclaims any
intent or obligation to update these forward-looking statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g498361arca.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g498361arca.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`%L!`0,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/>KB>.VB,DAP!7/B,13PU-U*CT148N3LC)/B$9^6VR/]_\`
M^M7S;XE5_=I?C_P#K^J>8X:\3TM?_(G_`-:MZ>>3G_RZ_P#)O^`)X9+[0[^V
MS_S[?^/_`/UJZ5FL_P#GW^/_``"?JZ[@=;(_Y=O_`!__`.M4RS::_P"7?X_\
M`/JZ[C#KY'6U_P#(G_UJXY\02AO1_P#)O^`6L+?[1-:ZW%/*(Y(_*ST.[(KH
MPF?4Z]3DG'EOYW_1$3PSBKIW-2OHCE"@`H`*`*IU"V%^++S!YY7=M]J`+5`!
M0!'--%;QF2:18T'5F.`*`*RZQIK'`OH"?]\4`#:MIR'#7L(/NXH`0:SII.!?
M09_WQ0!<CD25=T;AE]0<T`.H`*`$)`&2<`4`9USK^F6AQ+>1Y'8')H`J#Q?H
MY8#[0PST)7B@"W%K^E2C*WL0_P!YL4`:".LB!T8,IY!'>@!U`!0!6N[^VL?+
M^T2!/,;:OUH`L@Y&10`4`%`!0!S_`(@F;SHX<_+C=7QG$5:3J1I=+7._"Q5G
M(S(DS7EX7#7U9TR=BW%%E@I&*]ZE02T,'(LI;'>RD=!7;##ZM&;GH1^1^[+$
M<#BH=#W;L?-K8K.G'3BO-K8=-:FJD57!0YKYZO1=)W1NG<ZS3IC/8QL>N,&O
MT++:SK8:,GN>55CRS:+5>@9!0`R6188FD<X51DDT`>2'79#XI_M/)QYF,>W2
M@#UN*198DD4Y5AD&@!]`$<\$5Q$T4R!T;J"*`.$\::#8:=8I>6D(BDW;3CH:
M`*/@O1K35YIY;Q/,6+@*?6@#LKGPGH]S$5^R*C8^5EX(H`X$7]_X6UR2!9F>
M.)L%6/#"@#U*RNDO;*&YC^Y*H84`%Y>0V%J]Q<.$C09)H`\YNM;U3Q5J0LK$
MM%`3P%XX]2:`.OTKPGIVG(K21B>X_B=QG-`&K)IUE(A1[6$KC'W!0!Q'BKP?
M';V[WVFI@(,O'_44`=7X;F$_AZR8')$8!^M`&K0`4`>8>.-5^U:R+>-CLMAU
M'0F@#N_#VH#4M$MY\_-MPP]"*`-2@`H`*`.;U_\`Y"$8_P!C^M?&9Y#FQD%Y
M'HX7X&5K="Y`'7L*VPU)/1%3=C4BB`C(G&S:,AJ]F$$H^_I8YF]?='QW8=P8
MX^VW)[UI"LI.\42X66I*421%1AL`Y^M:N*DK,F[6J*-S"Y^;9M0=*X*U-O6U
MD;0DD9<XXZU\]C*2:9U09TFC?\@Y*^ER?3"1.#$?&R_7K&`4`<QXUU%[;3$L
M;<YN+MA&%[X[T`<GXRT5=)M-/DA7"!-C'U:@#KO`^J?VCH"(S9D@.PYZT`=+
M0`4`<?\`$5MN@)_UT%`&?\-'W+??44`>@4`>/^-;A9?$T\<7++\I`]:`/2_#
MD$EMX?LXI1AP@R/2@#B_B)K#->1Z:CD(@WN!WS0!M>`--6WT?[:R_O9S^0%`
M'7T`%`#9$62-HV&588(H`KV%A#IMJ+>W!$8.0#0!:H`HZQJ"Z7I5Q=L0-B_+
MGN>U`'`RZ(\W@B74G4BZDD\]\]0OI0!/\.-5Q-/I[MPPWKG^5`'HM`!0`4`<
MSX@/_$RB'^Q_6OD<X_WR/H>CAOX;(;81DC=)M_"M\,HO=CG=;(NWL@33P(Y2
MZYYR.E=6-J<E))/0RIJ\]4,LIE7&:TPU1)!4BR]-=*=NWJ*[)U5T,8Q(KWRF
M)+3D-CICI6-?E>\BZ=ULC$N"HX!R*^?Q=K.QV0.DT7_D&I7O93_NJ.#$?&:%
M>J8!0!YP^K6>J>/_`#;JYCCM+$?NRQQEJ`-?Q7J.C:KX?N(4OH&F4;HQN[T`
M<G\.]7^R:Z;1V^2X7:,GC(H`]<H`*`.+^);;?#R'_IJ*`.7\#ZO>:<+LVNG/
M>JQ!;8V"M`%_4_B7>#?;0Z>;68?*?-.2M`&MX8\(6Q*:O>7`O99?G4]@:`.W
MH`\/\93N?$UYOX(.!]*`/7/#@`\/V6T`#RP>*`-2@`H`*`"@`H`X'Q[J<4U_
M8Z*90D<CAIR3C:.U`'0MK&@FP^Q'4(#%LV8W#IB@#R:POQHOB9)HY`\<<O5>
MA!-`'N<4BRQ)(IRK`$&@!]`!0!RGB5MNI1?]<_ZU\=G<N7%Q]#T\(OW;*EM,
MBD%AN]J>&JQ6Y<XOH;"NMW:.DV(X.V.N:]>2CB:3C/1'+K"5UN43I]Y`P"@.
M",C'I7G1PV*HNUKFWM(2+EK;-&R2W+A0?NX]?>O0HTYIJ55V,IR3TB1WMT2Q
M29`6'0CBEB*W22'3AU1C7$@YYXKYW%5+)G9!'5Z'_P`@N.OI\G_W6)YN)_B,
MTJ]8YS%\5:LNB^'KJZ+;7V[$/^T>E`'.>#/"EE=>'X[S4[427-P2[;NU`'0?
M\(=H7_/A'0!Y!KMO)X:\62)'E$BD#QG_`&:`/<=,O4U'3+>\C^[*@84`6Z`.
M&^*3;?#<?_744`9GPE?<FH_[PH`L?$GPWYUM_;%JG[R,8F`'5?6@#,^&WBD6
M\_\`8]W)B*3F$GL?2@#U>@#QCXEV+V7B3[1M(AN$&T^I[T`=[\/M474O#$*[
MOWL'R,/3TH`ZJ@`H`*`*T.H6D][-9Q3J\\(!D0'E:`)9YDMH))I#A(U+,?84
M`>;>%K"+Q;KVIZO?Q^;;AMD0;H1VH`[#_A#M"_Z!\=`'G'Q%T*'1;VWGLX_+
MMY5P0.@:@#NOA_J_]J>&8E8YDM_W;>I]Z`.JH`*`.2\5*RWT+X^79C/O7Q?$
M$6J\9=+'J8)^XT8T<N*\RA7MHSJE$O0W99UW'Y1VKVJ6(NU=G/*%MC0AU(FX
MD<MQL(%=\,7>3=^AA*EHD0-?;[<Q,>AR#Z5B\3>'*RU3L[HHS71=0"<XZ5YU
M;$W5F;QA8IO)NXKQ:U3F9NE8[G1(VCTJ$-U(S7WF50<,+%,\;$-.H[%YG5!E
MF"CU)Q7IF!Y#X]\1VNM^(K'1H9PUG'*!,X/RD_\`UJ`/6;188[6**%E9$0*-
MISP!0!.2`,GB@#R7XO6UNDUE?)(AE;,;*#SCUH`N?##Q7;&Q.CWDZQS(V8BY
MP&!["@#TP.A7<&!'KF@#SOXLW]L-!AMEG0S-("%!R<4`9'PDU*UAN+ZUFF5)
M9,,@8XR*`/676*XA:-MKQN,$=010!X#XQT.;PMXA81$K`[>9`X[<]*`/4?!7
MC2TUW3(X;FX2._C&UU8XW>]`&GXI\.V_B?2&MRX69?FBD'.TT`>1Z-J^I?#_
M`,1/#?0.(2=LJ=F']X4`>V:7K%AK%HES97"2HPZ`\CVQ0!>)P,GB@#EO%GC6
MP\.63!94EO&&$B4YQ[F@#&^%V^\L;_6;ELSW4Q#,>^*`'?$SQ3#I^BMIUK,K
M7=QP0ISM7WH`V?`5O:V?A.SC@E1]PWM@C.30!T]`''?$FVM[KPE</)*BR6_[
MQ`3R3Z4`>=_#CQ1#HFL-!>2;+:Y`7<3PC>M`'N44T4R!HI%=2,@J<T`/H`HZ
MIIJ:E:F)CAARK>AK@QV"CC*7(]^AM1JNE*Z.(N],O;*0K)`Q'9E&0:^'KX#$
M8>5I1/8A6A-73*ZBX7_EC)_WR:F+JQ^R_N*?+W)`UP.D,G_?-;JI46T63:/<
M0F<_\L9/^^34N=3^5CM'N,V7#'`ADS_NFN>4:LOLO[BKQ74V=(\/W%Q*LMRI
MCA4YP>K5ZV`R>I5FIU5:*_$Y*V)C%6CN=FJA%"J,`<`5]K%**LCRF[F-X@\-
M6_B)(4N;FXB2(D[87V[OK3$8/_"JO#O]V?\`[[H`V=`\)VOAV5WM;JZD5A@)
M+)N5?I0!L7MJM[9RVS.Z+(NTLAP1]*`./;X7:)*Q>XGNYW)^])+DT`-/PI\.
MXX^T*>Q$F"*`-BT\(VUEH<VE1WMX8I#G>TF77Z&@#''PKT$\RR74K]V>7)H`
M#\*O#V/E-PA[,LF"*`.CT#08?#]H]M!<W$Z,V[,S[B/84`,\1>&=/\36:6U^
MK;4;<K(<,#]:`.?'PJ\/+]W[0I]1)@T`=-H>BQ:%8_9(9YIDSD-,VXCVH`DU
M/1=.UB#RK^UCF7MN'(H`Y!OA=:6DYGTG4[NR<GD!\C\*`)V\$ZO,`D_BF]>+
MNN:`&V_PJT&)_,G>XN7/),LF<T`=`_AJP&A/I%KOM+=N\+;6'XT`8!^%?A]C
MF1KF1^[-)DF@"YIGP_TS2+Z*YL[F[3RSGR_-^4_44`=8>F*`..O/AQI6H73S
MW=W>S;CG8TORCZ"@"#_A5/AS^[/_`-]T`:N@^#++P[=--9W5TRL,>7))N4?A
M0!T=`!0`8[4`-\M/[H_*IY8]AW8>6G]T?E1RQ[!=AY:?W1^5'+'L%V`10<A0
M/PI\J70+L=3$%`!0!@'Q)YFN+I<%LQD!^<MQ@>M`&_0!0U;5(M(L_M,RLRYQ
MA10!9M;A;NUCN$!"R+D`T`34`%`!0`4`5=1OETZS>X=&=5ZA10!5T+5GUBU>
MY,/E(&PG.<CUH`U*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`(YYEM[>29SA44L?PH`\\TG78;>\O\`5YHWGF<D1A!G:OO0!W6E:E%J
MNFQ7L((20=#VH`RM0\3V,6I0Z=Y)N&=L$XRHH`WRT<,6XD)&HSZ`"@#GW\70
M;9+B.VD>QB;:\^.,^U`&_'-')`LR,#&R[@?:@#B]5\07-WXA@M])WSQV_P`T
MBQ_Q>HH`Z+0]>@UN*4QHT<D+;71NQH`H>-K\6FAF$'#7#"/Z"@"A:>);70]/
ML[5;:22$81I@/E)]J`.RC=9(U=3E6&10!0OM9MK)S'AI9E&XQQC)`]:`*^A:
M\-<\]XX&CBC;`9N]`$.L^*K32)UA,;ROD!MO1:`&6WBVVN]6ALHK>8I*/EEV
M\9H`T-7UJVT>V,LV7;'"+U-`&._CBU&FBZCMY)"/OA1PGUH`6Y\<6<5O#-%!
M)*CXW,!POM]:`.EAE$\$<J@@.H8`^]`%6]U2WLG$1W23L,B)!EC0!2T;Q"NL
MW=Q'%;ND4/!9O7TH`VZ`"@`H`*`"@`H`*`"@`H`*`"@#EO'&H/;Z5'90'$]V
MX1:`,^YM8-"T&/1[-!)J5Z`K8&2,]2?2@#J=)L(](T:&U)`6)/F/\Z`./T1K
M/4O%;W9VQV\+&.VC'4MW-`&IX^O);?1X+>/(^U2B(D=A0!G^)U6P\/6.@6X!
MFN"%95Z_6@#KK9!INB1I-R((<-^`H`Y/PBT:IJFOS;5B9CY9Z`**`+/@*UE$
M%]J#@B.ZE+1^XH`J:_&?$'B^#30VVWM5W3'TH`L^)[=+R72M%L`OWP[;>0%%
M`&SX@U,:'HNZ+'G'$<0/K0!S&JWZ:+HZ64$@FU6^'[R3.<9]Z`.H\+P6UKHD
M,-NP;;]\_P"UWH`Y?7;9=<\8PZ7;@+'"-\Y'>@#O(+:&WB2..-55!@8'2@#C
MO&TOVB[MM*LXPU[=<,W<)F@#.U:R"M8^%=.`+GY[AQW]<T`%U':2Z[::/&PC
MT^QP9&'\;^]`'::SJD>C:+)=@#"J`@]^U`'*7.JIH>AFZ>43ZO?C.0<[,_RH
M`W/!UO#:Z/L5P]P3NG(_O&@#HJ`"@`H`*`"@`H`*`"@`H`*`"@#)UO0+77%A
M\]G1X&W1LAP0:`'Z;H=IIC-*F^6=NLLIW,?QH`NW5NEW:RV[DA)%VDCK0!F:
M+X9T_0]S6ZL\A_C<Y(^E`%S5-+MM6M/L]R#MR&4CJI]10!4L?#EI9WQOI'DN
M+HC`DE.=H]J`,[QYJ#6FA_9H3B>Z8(@]?6@!-.\'VR:7;6\L\YAP'>'=\I;O
M0!T\44<,2Q1($11@`=J`,EO#-B?M[*91)>C$C[N1]/2@"71]!M-&0B$O)(1C
MS)#EL>E`"ZWH5KKMJD%R7`1MP*G!%`&9/X&TF9+92)%,!SN#<M]30!T-O;Q6
ML"PPH%1>@%`%*PT.STZ]N+R$.9YSEV=L_E0!I4`9L>A64>LOJN':Y88RS9"_
M0=J`&V6@65CJ=SJ$0=KBX^\SMG'T]*`*UCX3TZQU.:_4/)+*VXASD`T`7M8T
MBWUK3VL[G=Y9(;Y3@Y%`&/+X&TJ6SCMR9?D.=^[YC0!OV=E!86R6]N@1%&/K
M0!8H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`*D^EZ?=2+)<6-O,ZG*
MM)$K$'VR*`+2J%4*H``Z`4`+0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0
%`4`?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
